ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function by Sharma, Aarti et al.
ARTICLE
Received 22 Jul 2015 | Accepted 14 Dec 2015 | Published 4 Feb 2016
ALS-associated mutant FUS induces selective
motor neuron degeneration through toxic gain of
function
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Mutations in FUS cause amyotrophic lateral sclerosis (ALS), including some of the most
aggressive, juvenile-onset forms of the disease. FUS loss-of-function and toxic gain-of-
function mechanisms have been proposed to explain how mutant FUS leads to motor neuron
degeneration, but neither has been firmly established in the pathogenesis of ALS. Here we
characterize a series of transgenic FUS mouse lines that manifest progressive,
mutant-dependent motor neuron degeneration preceded by early, structural and functional
abnormalities at the neuromuscular junction. A novel, conditional FUS knockout mutant
reveals that postnatal elimination of FUS has no effect on motor neuron survival or function.
Moreover, endogenous FUS does not contribute to the onset of the ALS phenotype induced
by mutant FUS. These findings demonstrate that FUS-dependent motor degeneration is not
due to loss of FUS function, but to the gain of toxic properties conferred by ALS mutations.
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A
myotrophic lateral sclerosis (ALS) is a fatal neurological
disorder characterized primarily by the rapid degenera-
tion of motor neurons (MNs). Mutations in over 20 genes
account for about 10% of cases1, but how mutations in each of
these functionally diverse genes cause selective MN degeneration
is unknown. The identification of the DNA/RNA-binding protein
TDP-43 as a component of abnormal, cytoplasmic inclusions in
sporadic ALS patients2 and the later discovery of ALS-causing
mutations in the TDP-43 gene (TARDBP)3 led to the
identification of causal mutations in the gene encoding the
related protein FUsed in Sarcoma (FUS)4,5. Together, these
findings suggested that aberrant RNA processing may underlie
common mechanisms of neurodegeneration in ALS6 and focused
attention on the normal activities of TDP-43, FUS and other
ALS-associated RNA-binding proteins7.
Over 50 mutations in FUS have been found in ALS families8,
the majority of which are dominant, missense changes clustered
in and around the C-terminal nuclear localization signal9.
FUS mutations are associated with a broad range of clinical
phenotypes including some of the most aggressive, juvenile-onset
forms of the disease10. How mutant FUS causes ALS is unknown,
but both gain- and loss-of-function mechanisms have been
proposed8. The toxic gain of function may relate to the
formation of abnormal aggregates of FUS in the nucleus and
cytoplasm of affected neurons and glia in ALS patients with FUS
mutations11,12. Alternatively, an excess of FUS activity may lead
to MN degeneration, as suggested by the identification of non-
coding mutations that increase the levels of non-mutant FUS13 in
ALS patients and by the finding that overexpression of wild-type
(WT) FUS in mice causes MN degeneration14.
FUS is a predominantly nuclear protein that plays multiple
roles in DNA damage repair and in RNA transcription, splicing,
transport and translation15,16. In neurons, FUS is also localized
to dendrites and accumulates at excitatory synapses as an
RNA–protein complex17 associated with N-methyl-D-aspartate
receptor (NMDA) receptors18 and in RNA transporting granules
in the soma and dendrites19. These data suggest that FUS, like
TDP-43 (ref. 20), could play a role in the modulation of synaptic
activity in the central nervous system by regulating mRNA
transport and local translation in neurons. Whether any of these
diverse activities of FUS is required for MN survival is not known.
Thus, the role of FUS function in ALS remains to be determined.
To study the mechanisms of mutant FUS-mediated MN
degeneration, we generated an allelic series of targeted,
conditional transgenic mice in which a single-copy, WT or
ALS-associated mutant human FUS (hFUS) is conditionally
expressed from the MAPT (tau) locus. Analysis of these mutants
reveals progressive, age- and mutation-dependent MN degenera-
tion that faithfully models several key aspects of the ALS
phenotype, including selectivity for MN subtypes most vulnerable
in the human disease. MN loss in this model is associated with
early synaptic failure and withdrawal of the motor axon from the
neuromuscular junction. We demonstrate that expression of
mutant hFUS is sufficient to cause MN degeneration, and that
alleles associated with aggressive, juvenile-onset forms of ALS are
more pathogenic in our disease models.
To determine whether the toxicity of mutant hFUS is a
consequence of FUS loss of function, we generated a conditional
FUS knockout mouse to demonstrate that long-term survival of
MNs in vivo is not dependent on postnatal FUS. These data
provide genetic evidence that MN degeneration in ALS-FUS is
not a consequence of FUS loss of function, but a toxic gain of
function conferred by ALS-associated FUS mutations. To test
whether this novel toxic function depends on the presence of WT
FUS, we combined the FUS transgenic and knockout mutants to
express exogenous mutant FUS in the context of reduced
postnatal FUS. These studies demonstrate in vivo that the ALS
mutant hFUS is not dependent on endogenous FUS to initiate
MN degeneration, arguing against a ‘seeding’ mechanism21 in
which mutant hFUS interacts with WT FUS to induce the
formation of toxic aggregates. Moreover, the finding that FUS
elimination has no effect on the onset of MN degeneration in our
model argues that an excess of FUS activity alone does not cause
MN degeneration. Together, these data support a disease model
in which ALS mutant FUS causes MN degeneration through a
toxic gain of function mechanism that does not involve the
normal activity of FUS.
Results
Generation and characterization of ALS-FUS mutant mice. To
investigate the mechanisms by which ALS-associated mutations
in FUS cause MN degeneration, we generated a series of targeted
transgenic mouse lines expressing WT or ALS-associated, mutant
human FUS from the mouse MAPT (tau (t)) locus22. cDNAs
encoding WT human FUS (hFUSWT) or one of two mutant
isoforms—hFUSR521C associated with typical, adult-onset ALS,
and hFUSP525L found in patients with an aggressive, juvenile-
onset form of the disease10—were introduced (Fig. 1a,b) into the
first coding exon of tau, preceded by an N-terminal myc tag to
label the exogenous hFUS protein. The t-hFUS alleles were made
conditional by placing a transcriptional stop flanked by loxP sites
50 of the hFUS cDNA (Fig. 1a) so that the recombinant tau allele
is silent until activated by Cre-mediated recombination
(Supplementary Fig. 1A). The three conditional t-myc-hFUS
mouse lines are referred to as tOFFhFUSWT, tOFFhFUSR521C and
tOFFhFUSP525L.
To express hFUS constitutively in all t-expressing cells, we
crossed the three tOFF conditional mouse lines to the Prm1-Cre23
germline CRE deleter to generate the tONhFUSWT,
tONhFUSR521C and tONhFUSP525L lines. In each of the three,
heterozygous tONhFUS mouse lines, no significant change in the
level of endogenous mouse FUS (mFUS) or tau was observed
(Fig. 1d). Compared with endogenous mouse FUS (mFUS), the
slowly migrating (90 kDa) myc-hFUS protein was expressed at
low levels and could not be detected by western blot analysis of
spinal cord extracts by any one of a series of FUS antibodies
(Fig. 1d; antibodies listed in Supplementary Table 1). However,
after enrichment by myc or FUS immunoprecipitation followed
by western blot analysis with a FUS or myc antibody, respectively,
exogenous hFUS was detected in the tONhFUSR521C and
tONhFUSP525L samples (Fig. 1e).
Western blot analysis also showed that the levels of hFUSR521C
and hFUSP525L wereB4 times higher than hFUSWT in the spinal
cord and brain (Fig. 1d). All hFUS transcript levels were
equivalent in brain and spinal cord of the three lines (Fig. 1c;
primers listed in Supplementary Table 2), so this increase could
not be explained at the level of transcription. However,
cyclohexamide blockade of translation in embryonic stem
cell-derived MNs from each of the three thFUS mutants revealed
decreased turnover of the mutant protein (Fig. 1f,g). Together
these data demonstrate that the accumulation of mutant versus
WT hFUS is due to increased stability of the ALS-associated
mutant proteins.
Mislocalization of ALS mutant human FUS in MNs. In ALS
patients with mutations in FUS, the predominantly nuclear FUS
protein is mislocalized to the cytoplasm of neurons and glia24.
Immunohistochemical analysis of the tONhFUS mutants
demonstrated expression of myc-hFUS in neurons and
non-neuronal cells (Fig. 2a) in a pattern consistent with the
known pattern of MAPT expression in the spinal cord25–28. In
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the myc-hFUSWT control mice, both hFUS and mFUS remained
predominantly nuclear (Fig. 2a,c), however, in the tONhFUSR521C
and tONhFUSP525L mutants, myc-hFUS was found mislocalized
to the cytoplasm and dendrites of t-expressing MNs (Fig. 2a,b),
and mutant hFUS protein was also detected peripherally in the
sciatic nerve (Figs 1d and 2c). Notably, the more pathogenic
hFUSP525L protein mislocalized to a greater degree compared
with hFUSR521C, as shown by a higher cytoplasmic/nuclear ratio
(Supplementary Fig. 2B). In contrast, endogenous mFUS
remained localized to the nucleus and below levels of detection
in the cytoplasm of the tONhFUSR521C and tONhFUSP525L
mutants. Despite the marked cytoplasmic mislocalization of
mutant hFUS, we observed no large, discrete cytoplasmic
aggregates in lumbar spinal MNs in the tONhFUSR521C or
hFUSP525L mice. These data demonstrate that ALS-associated





























































































































































Figure 1 | Conditional expression of myc-tagged hFUS from the MAPT locus reveals increased stability of ALS mutant protein. (a) Organization of the
endogenous (t) and targeted (tOFF)MAPT locus on mouse Chromosome 11. An hFUS expression cassette (light blue) was introduced into exon 2 of MAPT,
replacing the endogenous start codon. Excision of the LOX-STOP-LOX transcriptional stop sequence by Cre-mediated recombination allows expression of
the myc-tagged hFUSWT, hFUSR521C and hFUSP525L cDNAs from the tON allele of the MAPT locus. (b) Southern blot analysis of targeted ES cell clones
following BamHI digestion and hybridization with a 50 external probe (green, a). Wild-type ES cells (left, þ /þ ) display a 9.0-kb band. Targeted ES cells
(right, þ /tOFF) yielded a 3.3-kb band corresponding to the tOFF allele in addition to the 9.0-kb band corresponding to the untargeted allele at the MAPT
locus. (c) RT–qPCR analysis of hFUS transcripts in total brain and total spinal cord (p90, N¼4). Data are represented as mean and s.e.m. (d) Western blot
analysis of total spinal cord, brain and sciatic nerve extracts. 7x myc-tagged hFUS migrated at a higher molecular weight (90 kDa) relative to endogenous
mouse FUS (73 kDa). Immunoblotting with anti-FUS antibody did not detect myc-hFUS. All mutants analysed were heterozygous for the tONhFUS alleles
(with the exception of Supplementary Fig. 4A–C) and tau expression was maintained in these animals. (e) Immunoprecipitation of P90 mouse spinal cord
extracts with anti-myc or anti-FUS antibodies. myc-hFUS bands were detected with an anti-FUS antibody following immunoprecipitation with an anti-myc
antibody. (f) Western blot analysis of cyclohexamide (CHX)-treated embryonic stem cell-derived motor neurons (ESMNs). At 16 h post CHX treatment,
myc-hFUS was no longer detected with anti-myc antibody in cells derived from tONhFUSWT animals but persisted in tONhFUSR521C and tONhFUSP525L
samples. Levels of endogenous mouse FUS detected with anti-FUS antibody were similarly decreased in all samples. CyclinB1 was used as an internal
positive control for CHX treatment efficacy. (g) Quantification of myc-hFUS levels, normalized to myc-hFUS levels at 0 h, in CHX-treated ESMNs. Data are
represented as mean and s.e.m. of N¼ 3 differentiations.
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the cytoplasm, axon and dendrites of neurons, modelling a
pathological hallmark of ALS-FUS. Moreover, the degree of
mislocalization of hFUSP525L versus hFUSR521C in this mouse
model correlates with the relative toxicity of the respective
mutant FUS alleles in ALS patients.
Selective MN loss and weakness in ALS-FUS mutants. To
determine if ALS mutant FUS expression in the tONhFUSR521C
and hFUSP525L mice was associated with MN degeneration, we
used an antibody against choline acetyl transferase (ChAT) to
visualize and count spinal MNs at lumbar level 5 (L5; Fig. 3a). At
postnatal day 10 (p10), there was no significant difference in the
number of ChATþ L5 MNs in the mutants compared with age-
matched tONhFUSWT and WT littermate controls (Fig. 3b),
demonstrating that expression of hFUSR521C or hFUSP525L had
no developmental effect on the number of MNs generated.
We observed the first significant loss of MNs at p30 in the
tONhFUSP525L mutant, but no significant MN loss in the tONh-
FUSR521C at that age (Fig. 3b). However, the number of ChATþ
MNs was significantly reduced in both the tONhFUSR521C and
tONhFUSP525L mice at p60 (Fig. 3b). MN loss progressed
steadily in both mutants to p360, but was more pronounced in
the tONhFUSP525L mutant (B30%), compared with the tONh-
FUSR521C mice (B20%; Fig. 3b), demonstrating that the mutant
allele associated with juvenile-onset ALS is also more pathogenic
in this mouse model of the disease. Moreover, only mutant
hFUS was toxic to MNs in this system as, in contrast, no sig-
nificant loss of L5 MNs was observed in the tONhFUSWT control
(Fig. 3b).
To determine if neuronal loss was selective to MNs in these
mutants, we counted parvalbumin (PV)-positive, proprioceptive
sensory neurons in the L5 dorsal root ganglia and found no
significant difference at p360 in the tONhFUSP525L or FUSR521C
mutants relative to controls (Fig. 3c,d). Also we found no
significant MN loss at p360 in oculomotor nucleus (Fig. 3c,d), a
MN subpopulation spared in ALS patients and in the mutant
SOD1 model of disease29. However, as in ALS patients
and the SOD1G93A mouse30–34, MN degeneration in the




























Figure 2 | Diffuse cytoplasmic mislocalization of mutant FUS extends to sensory and motor axons in the peripheral nerve. (a) Confocal images of L5
spinal cord cross-sections of hFUSWT (left), ALS mutant R521C (centre) and P525L (right) animals immunostained with anti-myc and anti-FUS antibodies.
hFUS was detected by anti-myc antibodies in both the grey and the white matter (boundary marked by the dotted white line), consistent with the normal
pattern of Tau (MAPT) expression in all neurons and in subpopulations of glia, including oligodendroglia and astrocytes25–27. Scale bar, 100mm. (b) Higher
magnification confocal images of L5 MNs, as in a. hFUS-WT protein was detected with anti-myc antibody (top, left) exclusively in the nucleus, whereas
hFUS-R521C (top, centre) and hFUS-P525L (top, right) were detected both in the nucleus and in the cytoplasm of the MNs. Immunohistochemical staining
with anti-FUS antibody (bottom) detected nuclear but not cytoplasmic FUS in all samples. Scale bar, 25mm. (c) Cross-sections of sciatic nerves stained
with anti-myc (red), anti-ChAT (green) and anti-MBP (myelin basic protein, blue) antibodies. hFUS-R521C and hFUS-P525L proteins, but not hFUS-WT,
were detected in motor and sensory axons in the peripheral sciatic nerve. Scale bar, 40mm.
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microgliosis, evidenced by an increase in both glial fibrillary
acidic protein (GFAP) and Iba1 immunoreactivity in the ventral
horn of the tONhFUSR521C and hFUSP525L mutants relative to the
tONhFUSWT controls (Supplementary Fig. 1B).
Expression of mutant hFUS had no effect on the survival of the
tONhFUS mice; however, MN loss in the lumbar spinal cord was
also associated with significant hind-limb weakness. Wire hang
analysis at p360 demonstrated that the average latency to fall for
the tONhFUSR525L mutant was approximately half that of the
tONhFUSWT and WT controls (Fig. 3e).
These data demonstrate that ALS mutant hFUS, but not the
WT protein, is toxic to MNs in this model system, and that
hFUSP525L, the more pathogenic allele in patients, also causes
earlier and more pronounced MN loss in the mouse compared
with hFUSR521C. Moreover, neurodegeneration in the tONhFUS
mutants is selective to MNs and associated with significant
motor dysfunction, reproducing key aspects of the ALS
phenotype.
Early preferential denervation of fast twitch limb muscles. In
ALS patients, fast-fatigable (FF) motor units are the earliest
affected,35 and neurogenic changes in muscle can be observed
before MN loss36. Similarly, MN loss in the SOD1 mouse is also
preceded by denervation of skeletal muscles, with early and
preferential involvement of FF motor units37,38. To determine
whether expression of mutant hFUS results in the early
withdrawal of motor axons from muscles innervated by FF
motor units, we looked for evidence of denervation in three hind-
limb muscles innervated by L5 MNs, the tibialis anterior (TA)
innervated predominantly by FF MNs, the soleus (Sol) innervated
mostly by slow (S) MNs and the gastrocnemius (GS) innervated
by a mixture of S, fast fatigue resistant (FR) and FF motor units39.
Using an antibody against vesicular acetyl choline transporter
(VAChT) to visualize motor axon terminals and a fluorescent
conjugate of a-bungarotoxin (a-BTX) to label the post-synaptic
surface of the neuromuscular junction (NMJ), we found no
significant denervation of NMJs at p10 in any of the three
tONhFUS mice (Fig. 4a,b). By p20, however, before MN loss was
detected at L5, a significant number of NMJs (11.4%) in the TA of
the tONhFUSP525L mutants had no associated input (Fig. 4a),
demonstrating early retraction of motor axons. Similarly, in the
tONhFUSR521C mice, we observed significant denervation of the
TA at p40 before L5 MN loss at p60 (Fig. 3b). Denervation of the
GS followed at p90 whenB10% of NMJs were vacant in both the
tONhFUSR521C and tONhFUSP525L mice (Fig. 4a). Denervation in
both the TA and GS progressed steadily in these mutants so that
at p360 in the tONhFUSR521C mouse, 30.2% and 13.9% of
endplates were vacant in the TA and GS, respectively (Fig. 4a).
Similarly, in the tONhFUSP525L mice 36.7% and 19.3% of NMJs
were denervated in the TA and GS, respectively (Fig. 4a). In the
predominantly slow Sol muscle, no significant denervation was
noted at 1 year (p360) in the tONhFUSR521C, however, over 10%
of Sol motor terminals were vacant in the tONhFUSP525L mutant
at that time point (Fig. 4a). As further evidence of denervation,
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Figure 3 | Progressive and selective loss of motor neurons in the lumbar
spinal cord of mice expressing ALS mutant FUS. (a) Representative
images of L5 spinal cord cross-sections of control tONhFUSWT and
tONhFUSP525L p360 animals immunostained with anti-ChATantibody. Scale
bar, 100mm. (b) MN survival in tONhFUSWT (grey), tONhFUSR521C (blue)
and tONhFUSP525L (red) animals calculated from the number of MNs in the
L5 spinal cord normalized to that of non-transgenic wild-type controls
(expressed as a percentage). (c) Representative images of parvalbumin-
positive sensory neurons (PV, green, left) in the L5 DRG and MNs (ChAT,
green, right) in the oculomotor nucleus in tONhFUSP525L animals. Scale bar,
50mm (left), 100mm (right). (d) The number of parvalbumin-positive
sensory neurons in the L5 DRG (left) and the number of MNs in the
oculomotor nucleus (right) in p360 tON animals normalized to
non-transgenic wild-type controls (expressed as a percentage).
(e) Evaluation of hind-limb motor function at p360 using the wire hang test.
The latency for animals to fall was recorded over five trials with a 2-min rest
period between each trial. (For b, d and e: N¼4, *Po0.05, **Po0.01 and
***Po0.001 using one-way analysis of variance with Bonferroni’s post hoc
test. Error bars represent s.e.m.).
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(Supplementary Fig. 3B) were also observed in the TA of the
tONhFUSP525L mutant. The same results were found using other
pre-synaptic markers including synaptophysin, neurofilament
and synaptic vesicle protein 2, demonstrating that the apparent
denervation was not a consequence of VAChT downregulation in
the mutants (Supplementary Fig. 3A). As tONhFUS is not
expressed in the muscle, these data show that mutant FUS causes
the early retraction of motor axons from the neuromuscular
junction by a pre-synaptic mechanism, and that this pathology
preferentially involves the motor units known to be most
vulnerable in ALS.
As was the case with MN soma counts, no denervation of the
TA, GS or Sol muscles was observed in the tONhFUSWT control,
demonstrating that the phenotype was specific to mutant hFUS.
Here we also used TA denervation as a sensitive measure of MN
loss to test whether the selective toxicity of hFUSP525L and
hFUSR521C is a result of higher steady-state levels of mutant
versus WT hFUS. We analysed mutant mice that were
homozygous for the tONhFUSWT or tONhFUSP525L allele. In
each case, the level of hFUS RNA determined by reverse
transcription–quantitative PCR (RT–qPCR) was double in the
homozygous mutant compared with the respective heterozygous
control (Supplementary Fig. 4A). Western blot analysis of the
homozygous animals confirmed that the level of hFUS protein
was twofold higher than in the corresponding heterozygote
mutant, which was still too low to negatively regulate endogenous
mFUS expression (Supplementary Fig. 4B). In the homozygous
animals, the relative levels of hFUSP525L and FUSWT remained
approximately 4 to 1 (Supplementary Fig. 4B). No denervation of
the TA NMJs was detected in the homozygous tONhFUSWT
animals at p90 (Supplementary Fig. 4C), demonstrating that
hFUSWT even at twice the level expressed in the tONhFUSWT
heterozygotes is not toxic to MNs. Further, analysis of the
tONhFUSP525L homozygous mutants showed a comparable
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Figure 4 | Mutant FUS causes early synaptic changes at the neuromuscular junction, leading to progressive and selective denervation. (a) Denervated
NMJs in the TA, GS and SOL of tONhFUSWT (grey), tONhFUSR521C (blue) and tONhFUSP525L (red) animals normalized to controls. N¼4. *Po0.05,
**Po0.01 and ***Po0.001 using one-way analysis of variance with Bonferroni’s post hoc test. Error bars represent s.e.m. (b) Co-localization of VAChT-
positive motor terminals (green) with acetylcholine receptors (a-BTX, red) as a marker of innervated endplates. In tONhFUSP525L animals, denervated
endplates (arrows, top right), partially innervated endplates (asterisk, top right) and internal nuclei (arrows bottom left) were observed. Scale bar, 40mm
(top), 20mm (bottom). (c,d) Electron micrographs from TA NMJs in p30 tONhFUSWT (c) and tONhFUSP525L (d) animals, show that motor terminals (ax.,
green) were correctly opposed to postsynaptic folds (f) in the muscle (brown, m.f). Higher magnification of boxes 1 and 2 are shown in c1, d1 and c2, d2. In
tONhFUSP525L animals, the distributions of mitochondria (purple) and synaptic vesicles (yellow) were altered. Pre- (white arrows, d1, d2) and post-synaptic
structurally damaged mitochondria (yellow arrows, d2) with clear- and dark-vacuoles (d.v. and c.v., d2) were observed in tONhFUSP525Lanimals. Scale bar,
1mm (c,d), 0.4mm (for c1, c2 and d1,d2). (e) Quantification of synaptic vesicles, healthy mitochondria, postsynaptic folds and sarcomere length in NMJs
from tONhFUSWT (grey) and tONhFUSP525L animals (red). N¼6 junctions, 2 animals. (f) EMG responses in the TA following a 50-Hz, 1 s stimulation of the
sciatic nerve in tONhFUSWT (left) and tONhFUSP525L (right) animals. The first and last four responses are shown in an expanded time scale below. Blue
triangles mark the stimulus artefact. (g) M-responses at subsequent stimuli, normalized to the first response in tONhFUSWT (grey) and tONhFUSP525L (red)
animals. (N¼ 5. *Po0.05 using two-way analysis of variance with Fisher’s LSD post-hoc test. Error bars represent s.e.m.). (h) Spontaneous activity in the
TA of tONhFUSWT (left) and tONhFUSP525L (right) animals. Examples of spontaneous activity are shown in insets 1–3. (i) Frequency of spontaneous events
in tONhFUSP525L (red) and tONhFUSWT (grey) animals. (N¼ 5. *Po0.01 using t-test. Error bars represent s.e.m.).
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Abnormal NMJ structure and function early in FUS mutants.
Ultrastructural changes of NMJs in the TA muscle were also
observed in the tONhFUSP525L mice at p30 when morphological
changes were first seen by light microscopy (Fig. 4c,d). At this
early time point, mutant NMJs showed pre-synaptic abnormal-
ities, including a significant (B40%) reduction in the density of
synaptic vesicles (depicted in yellow in Fig. 4c1, c2, d1 and d2) in
the pre-synaptic terminals of the mutant (39.7±1.4 per mm2)
compared with aged-matched WT controls (64.3±6.6 per mm2;
Fig. 4c–e). However, the number of active zones—the main
apparatus for synaptic vesicle release—was unchanged in the
tONhFUSP525L mice compared with the tONhFUSWT control
(2.4±0.2 per mm 1 and 2.6±0.2 per mm 1, respectively). In the
axon terminals of the tONhFUSP525L mutant, the number of
morphologically normal mitochondria (6.3±2.0 per mm2) was
significantly decreased compared with control terminals
(34.1±10.1 per mm2; Fig. 4c,d, purple) and the remaining
mitochondria appeared dilated and vacuolated with disorganized
cristae and membranes (Fig. 4d and d1–2), comparable to that
described in mutant SOD1 and TDP-43 transgenic models of
ALS40. At the postsynaptic site, we also found evidence of
muscle degeneration in the tONhFUSP525L mice including
abnormal mitochondria (Fig. 4d). Further, the sarcomere length
in TA muscle of the tONhFUSP525L mutant (1.83±0.2 mm)
was significantly reduced compared with control fibres
(3.04±0.05 mm; Fig. 4e). These data suggest that early synaptic
changes in the thFUS mutant mice lead to severe NMJ
abnormalities and the consequent axonal detachment observed
in our immunofluorescent studies.
To determine whether these ultrastructural changes are
associated with physiological dysfunction at the NMJ, we used
electromyography (EMG) to record spontaneous and evoked
activity of TA MNs at the NMJ in the tONhFUSP525L and WT
control mice. Using a novel, in vitro sciatic nerve-hind-limb
preparation, we stimulated the sciatic nerve for 1 s at 10, 50 and
100Hz and recorded the evoked motor response from the TA
muscle. We detected no difference in the motor response in the
tONhFUSP525L mice compared with controls at 2 weeks of age
(Supplementary Fig. 5E,F), demonstrating no developmental
abnormality in NMJ transmission. At 3 weeks of age, there was
no significant difference in the average motor response
between control and mutant mice with low frequency stimulation
(10Hz; Supplementary Fig. 5A,B). However, at 50Hz there was a
significant (B45%) reduction of the motor response amplitude in
the TA of mutant mice compared with controls (Fig. 4f,g),
suggesting that mutant MNs cannot sustain reliable neurotrans-
mission at the NMJs and exhibit abnormal signs of synaptic
depression. At 100Hz, both control and mutant mice exhibited
synaptic depression as measured by the average amplitude of the
motor response (Supplementary Fig. 5C,D), however, in contrast
to the controls, the motor response in mutant TA MNs was often
completely absent, indicating a failure of neurotransmission. As
further evidence of dysfunction at the NMJ in the FUS mutant
mice, we observed a significant increase in spontaneous activity in
the tONhFUSP525L mutants, a sign of active denervation of
neurogenic origin (Fig. 4h,i). Although the frequency and
amplitude of these events were variable between mutants, control
animals did not exhibit any spontaneous events. Together,
these results provide strong evidence that in tONhFUSP525L
mutant mice, functional abnormalities in neurotransmission at
the NMJ precede gross morphological changes and motor axon
withdrawal.
Cell autonomous MN degeneration in FUS mutant mice. To
test whether expression of mutant FUS in MNs alone is sufficient
to cause MN degeneration, we used a ChAT-Cre deleter strain
crossed to the conditional tOFFhFUSWT, hFUSR521C and
hFUSP525L lines to express each hFUS isoform selectively in MNs
(Fig. 5a). We refer to this series of mice as the tMN lines.
Immunohistochemical analysis of the tMNhFUSR521C and
tMNhFUSP525L spinal cords revealed marked mislocalization of
mutant hFUS to the cytoplasm, dendrites and axons of MNs
(Fig. 5a,b). In contrast, WT hFUS remained localized to MN
nuclei in the tMNhFUSWT mice, similar to what we observed in
the tONhFUSWT controls (Figs 5a and 2b). Immunohistochemical
(Fig. 5b) and western blot analysis (Fig. 1d) of sciatic nerve also
detected myc-hFUSR521C and -hFUSP525L, but not -hFUSWT in
the periphery, confirming that ALS mutant FUS is selectively
mislocalized to motor axons in the tMN mutants.
To determine whether the selective expression of ALS mutant
FUS in MNs caused cell autonomous degeneration in vivo, we
counted all ChATþ MNs at L5 (Fig. 5c). At p10, there was no
significant difference in the number of L5 MNs in the
tMN mutants compared with the tMNhFUSWT and WT controls.
At p30, we observed significant MN loss in the tMNhFUSP525L
(11.8%, Fig. 5c) mutant mice compared with both tMNhFUSWT
and control animals. Significant degeneration was first noted in
the tMNhFUSR521C at p60 when 10% of all L5 MNs were lost
(Fig. 5c). This degeneration progressed in both ALS mutants until
approximately p240, and measured at p360 there were 18.6% and
22.6% fewer MNs overall in the L5 segment of tMNhFUSR521C
and tMNhFUSP525L mutants, respectively, compared with
age-matched controls (Fig. 5c).
MN loss in the tMNhFUS mutants was also associated with
significant (B10%) denervation of the TA NMJs, first observed at
p20 of in the tMNhFUSP525L mutants (Fig. 5d) before any
detectable MN loss at L5 (Fig. 5c), and at p60 in the
tMNhFUSR521C mice (Fig. 5d). Denervation of the TA muscle
progressed with age, and at p360 B30% and B25% of NMJs
were denervated in the tMNhFUSP525L and tMNhFUSR521C
mutants, respectively (Fig. 5d). Significant denervation was first
noted much later (p120) in the GS in both the tMNhFUSP525L
(B13%) and tMNhFUSR521C (B10%) mice (Fig. 5d), but even at
p360, no significant denervation was noted in the Sol in any of the
genotypes we analysed. Together, these data demonstrate that
selective expression of mutant hFUS in MNs is sufficient
to cause muscle denervation and MN degeneration by cell
autonomous mechanisms, preferentially affecting MN subtypes
most vulnerable in ALS.
FUS loss of function alone does not cause MN degeneration. In
ALS-FUS, mutant hFUS may cause MN degeneration either by
acting as a dominant-negative to inhibit normal FUS activity or
through a novel, toxic gain of function. A loss-of-function
mechanism would be consistent with our observation that mutant
hFUS as well as endogenous mFUS was excluded from the
nucleus in a significant subset of MNs in the tONhFUS mutants
(Fig. 6a), as reported in ALS-FUS patients24. At p120, FUS
exclusion was observed in B5–10% of L5 MNs in the
tONhFUSR521C and tONhFUSP525L mutants, and rarely in the
tONhFUSWT and WT controls. Nuclear exclusion of hFUS and
endogenous mFUS was also observed in a proportion of MNs in
the tMNhFUS mutant mice (Supplementary Fig. 2C).
To explore the role of FUS loss of function on MN
degeneration in the tONhFUS mutants, we generated a novel,
conditional FUS knockout (FUSFLOX) allele (Fig. 6b) to overcome
the perinatal lethality of the constitutive FUS knockout muta-
tion41. FUS transcript (by RT–qPCR (N¼ 3)) and protein
(Fig. 6c) levels in the postnatal brain were equivalent in the
FUSFLOX/FLOX and WT control, and homozygous FUSFLOX/FLOX
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and FUSFLOX/KO mutants showed normal postnatal survival.
Together, these findings demonstrate that before recombination,
the conditional FUSFLOX allele is fully functional and able to
rescue the perinatal lethality of FUS deficiency. We then crossed
the FUSFLOX mice to a germline Cre deleter strain to generate a
constitutive FUS knockout allele (FUSKO*; Fig. 6b) and found that
homozygous FUSKO*/KO* mutants die at birth and express no
detectable level of FUS transcript or protein at p0 (Fig. 6d,e).
These data demonstrate that upon recombination, FUSFLOX
generates a null (FUSKO*) allele.
To determine whether FUS deficiency in MNs causes
neurodegeneration, we used ChAT-Cre to selectively eliminate
FUS from MNs by generating mice heterozygous for the
FUSFLOX, FUSKO and ChAT-Cre alleles (referred to as
FUS-KOMN mutants). We reasoned that if ALS mutant FUS acts
as a dominant negative to cause MN degeneration in the thFUS
mutants and ALS-FUS patients, then the complete deletion of
FUS from MNs would result in at least comparable if not more
severe loss of MNs in the FUS-KOMN mice. Analysis of the
FUS-KOMN mutants revealed selective and nearly complete
elimination of FUS from MNs in the ventral horn of the L5 spinal
cord by the end of the second postnatal week (Fig. 6f,g).
Remarkably, despite this cell autonomous loss of FUS, no
appreciable MN degeneration was observed in the FUS-KOMN
mutant compared with controls even at 1 year of age (p360), as
measured by the number of L5 MN somata and the extent of
denervation of NMJs in the TA muscle (Fig. 6h).
As a further test of whether FUS loss of function could cause
MN degeneration, we used a ubiquitously expressed, tamoxifen-
inducible Cre deleter (UBC-CreERT2 (ref. 42)) to induce
widespread, postnatal elimination of FUS in the central nervous
















































































































































Figure 5 | Motor neuron-selective expression of mutant FUS results in degeneration of MNs and denervation of fast muscles. (a) Conditional
expression of myc-tagged hFUS proteins (grey, top) in cholinergic cells of tMNhFUSWT, tMNhFUSR521C and tMNhFUSP525L animals. hFUS expression was
restricted to cholinergic cells, as determined by the co-localization of myc (red, bottom) with ChAT (green, bottom). Scale bar, 100mm. (b) Cross-sections
of the sciatic nerves from tMNhFUSWT (left) and tMNhFUSP525L (right) animals stained with anti-myc (red), anti-ChAT (green) and anti-MBP (blue)
antibodies. Co-localization of hFUS and ChAT in motor axons (yellow) was observed in tMNhFUSP525L but not in tMNhFUSWT animals. Scale bar, 20mm.
(c) MN survival in tMNhFUSWT (light grey), tMNhFUSR521C (light blue) and tMNhFUSP525L (orange) animals calculated from the number of MNs in the L5
spinal cord normalized to that of non-transgenic wild-type controls (expressed as a percentage). (d) Percentages of denervated NMJs in the tibialis
anterior, gastrocnemius and soleus muscles of tMNhFUSWT (light grey), tMNhFUSR521C (light blue) and tMNhFUSP525L (orange) animals normalized to non-
transgenic wild-type controls. (For c and d: *Po0.05, **Po0.01 and ***Po0.001 using one-way analysis of variance at each time point with Bonferroni’s
post hoc test. Error bars represent s.e.m. N¼4 for all genotypes.)
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recombination (Fig. 7a) led to the loss of FUS immunoreactivity
in a large majority of all neuronal and non-neuronal cells in the
L5 spinal cord (shown at p240, Fig. 7b). Again, despite this early
and efficient elimination of FUS expression, no significant loss of
L5 MNs or denervation of the TA muscle was detected at p240
(Fig. 7c), well after MN degeneration was observed in the
tONhFUSR521C and tONhFUSP525L mice. Together, these data
demonstrate that postnatal FUS expression is not required for the
long-term survival of MNs in vivo and that FUS elimination does
not reproduce the MN degenerative phenotype observed in the
thFUS mutants.
FUS toxicity is unrelated to endogenous mouse FUS expres-
sion. The absence of a MN phenotype in the postnatal FUS
knockout mutant leads to the conclusion that MN degeneration
in the thFUS mutant mice is caused by a toxic gain of function.


































































































































NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10465 ARTICLE
NATURE COMMUNICATIONS | 7:10465 |DOI: 10.1038/ncomms10465 | www.nature.com/naturecommunications 9
below the levels of endogenous mFUS (Fig. 1d), MN toxicity may
be a consequence of excess of FUS activity. Our finding that the
ALS-related mutations increase the stability and steady-state level
of hFUS (Fig. 1d,f) is consistent with the idea that MN toxicity is
a function of increased FUS expression. Alternatively, mutant
hFUS may interact with mFUS to seed the formation
of toxic aggregates21,43,44. To test these possible gain-of-
function mechanisms, we generated inducible FUS knockout
(FUSFLOX/KO; UBC-CreERT2) mice that were also heterozygous
for the tONhFUSP525L allele to determine whether the elimination
of endogenous mFUS would delay the onset of MN degeneration
in the tONhFUS mutant. Postnatal treatment of these mutants
with tamoxifen (Fig. 7a) again resulted in elimination of
endogenous mFUS from a large majority (B90.0%) of NeuNþ
L5 spinal neurons (Fig. 7d). We used denervation of the TA
muscle at p60 as a measure of disease initiation to determine
whether this loss of endogenous FUS had any effect on the onset
of the tONhFUSP525L MN phenotype. Despite the widespread
elimination of mFUS, we found no difference in the degree of TA
denervation in this tamoxifen-treated mutant (B12%) compared
with littermate controls (B13%) in which mFUS was expressed
in all cells (Fig. 7e). These data provide functional evidence that
the toxicity of mutant hFUS is not a consequence of an excess of
total FUS. Consistent with our finding that mutant hFUS and
endogenous mFUS do not interact physically (Fig. 1e), these data
also demonstrates that mutant hFUS toxicity does not depend on
an interaction between mutant and WT protein.
Together, our data demonstrate that the selective toxicity of
mutant hFUS in the tON mice is not due to an excess of total FUS
or the mutation-related increase in hFUS stability, but rather to a
toxic gain-of-function specific to the ALS-associated mutant
protein.
Discussion
Advances in ALS genetics have led to the identification of a
multitude of genes in which mutations cause selective MN
degeneration. The discovery of each new ALS gene presents an
opportunity to generate novel models with which to explore
mechanisms of disease and to identify therapeutic targets shared
between distinct, familial and sporadic forms of ALS. ALS-FUS is
unusual in that a wide variety of clinical phenotypes are
associated with FUS mutations, ranging from common presenta-
tions of the disease to the most aggressive, juvenile-onset forms of
ALS reported. Here using a series of novel mouse models of ALS-
FUS, we demonstrate that FUS loss of function is not sufficient to
cause the selective and progressive loss of MNs associated
with ALS mutant FUS and that the toxicity conferred by ALS
mutations on FUS does not involve an excess of FUS activity or
require the interaction of mutant and WT FUS.
FUS expression is highly regulated and existing animal and
cellular models have shown that an excess of WT FUS activity is
toxic14, although not necessarily in a way that is relevant to ALS.
We modelled FUS-ALS by generating a series of targeted
transgenic animals in which equivalent levels of exogenous
hFUS transcript are stably expressed from a defined locus in a
consistent pattern, at or below endogenous FUS levels so as to
avoid any variance in the lines that may influence the MN
phenotype. Analysis of animals expressing mutant hFUS
selectively from spinal MNs (tMN) or more broadly from all
t-expressing neurons and non-neuronal cells (tON) revealed
progressive MN degeneration that selectively involves spinal MNs
and spares neuronal populations normally unaffected in ALS,
including oculo-MNs and other long projection neurons like
muscle spindle (IA) afferents in the dorsal root ganglia. We also
observed the preferential involvement of fast versus slow twitch
motor units in our models, demonstrating the selective loss of
specific, functional subtypes of spinal MNs most vulnerable in
patients and SOD1 mutant mice37. In contrast, no MN loss or
muscle denervation was observed in the heterozygous or
homozygous hFUSWT animals, demonstrating that the MN
phenotype we describe is dependent on the ALS-causing
mutation in hFUS. The molecular and cellular selectivity of
mutant FUS toxicity in this system demonstrates the relevance of
the tON-hFUS mouse model to FUS-ALS. However, the selective
involvement of a specific subset of MNs—while sufficient to cause
significant hind-limb weakness—does not influence the lifespan
of these mutants. Although this is in some respects a limitation of
the model, the early onset and steady progression of MN
degeneration, together with the specific, qualitative aspects
of the MN phenotype make the tON-hFUS mutants a highly
ALS-relevant system in which to explore disease mechanisms and
to test potential therapeutics.
The conditional nature of the t-hFUS alleles allowed us to
explore whether cell autonomous and non-autonomous mechan-
isms contribute to mutant FUS-dependent MN degeneration, as
in SOD1 mice45–48. We found that selective expression of mutant
hFUS in MNs caused MN degeneration with the same selectivity
as in the tON mutants. These data do not argue that ALS-FUS is a
cell autonomous disease, only that expression of mutant FUS in
MNs alone is sufficient to cause MN loss. Even in the tMN
mutants, evidence of astrocytosis and microgliosis suggests that
secondary, non-autonomous mechanisms may also contribute to
the MN phenotype in this model. Comparison of the tMN- and
the corresponding tON-hFUS mutant (Supplementary Fig. 3D)
did not reveal a significant non-autonomous effect in the
Figure 6 | Motor neuron-selective deletion of FUS does not cause MN degeneration. (a) MNs of tONhFUSWT (left), tONhFUSR521C (centre) and
tONhFUSP525L (right) animals immunostained with anti-myc (red, top) and anti-FUS (green, bottom) antibodies. White arrows indicate cells with no
nuclear staining for myc-hFUS (red) and endogenous mFUS (green). Scale bar, 25mm. (b) Illustration of the conditional FUS allele (FUSFLOX) and the null
FUS allele (FUSKO*). In the FUSFLOX allele, exons 4–6 of murine FUS are flanked by LoxP (red triangles) recombination sites. Cre-dependent excision of
exons 4–6 produces the FUSKO* allele. (c) Western blot analysis of total brain extracts with anti-FUS antibody in p10 wild-type controls (WT/WT) and
animals homozygous for the conditional FUS allele (FLOX/FLOX). (d) Using primers specific to exons 12–14, in p0 total brain extracts, FUS transcript
abundance in FUS null (FUSKO*/KO*, light grey) was 4.1±0.3% relative to wild-type controls (dark grey) animals. Similar results (6.7±0.8%) were obtained
using primers specific to exons 1–3 (N¼ 3). (e) Western blot analysis of total brain extracts from p0 wild-type (WT/WT), heterozygous FUS null (WT/
KO*) and homozygous FUS null (KO*/KO*). No protein products were observed in FUSKO*/KO* animals using N-terminal anti-FUS antibody (ab84078).
Similar results were obtained using antibodies raised to the middle and the C-terminus of the FUS protein (Supplementary Fig. 4D). (f) Quantification of the
fraction of MNs (ChATþ ) that were also FUSþ in control (black) and FUS-KOMN (grey) animals. The majority of MNs (67.1±5.6%) were already
immunonegative for FUS by p4 and by p30 the elimination of FUS from MNs was complete (99.5±0.3%). N¼ 3. (g) Immunostaining of L5 spinal cords
from p360 control (left) and FUS-KOMN (right) animals for FUS (red) and ChAT (white). Boxed area is reproduced at higher magnification in the bottom
panels. Scale bar, 100 mm (top), 25 mm (bottom). (h) Percentage of MNs in the L5 spinal cord normalized to control (top) and the percentages of innervated
NMJs in the TA muscle (bottom) in p360 control (dark grey) and FUS-KOMN (light grey) animals. N¼4. (For f–h: Control¼ FUSFLOX/WT;ChAT-Creþ /
and FUS-KOMN¼ FUSFLOX/KO;ChAT-Creþ / ).
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hFUSR521C model, but in the hFUSP525L mice the extent of MN
loss and the degree of denervation was significantly greater in the
tON versus tMN mutant, but only after p240. These studies show
that cell non-autonomous expression of mutant hFUSP525L had
no effect on the onset of MN degeneration, but did accelerate
disease progression in this mouse model of ALS-FUS. The specific
cell type(s) involved in the cell non-autonomous mechanisms of
disease progression in the tON mice remains to be determined,
but the predominant expression of MAPT in neurons and
oligodendroglia (Supplementary Fig. 3C) implicates these MN
partners in FUS-mediated MN degeneration.
MN degeneration in the t-hFUS mutants progresses slowly, but
the first evidence of pathology is detected remarkably early in the
most vulnerable motor units of the tONhFUSP525L mice. By the
third postnatal week, structural and functional evidence of
synaptic failure at the NMJ is first observed. Pre-
and postsynaptic changes in the ultrastructure of the
NMJ—including abnormal mitochondria and reduced synaptic
vesicle density—are associated with electrophysiological evidence
of active denervation of the TA muscle, including increased
spontaneous activity and sensitivity to high-frequency stimula-
tion. These early changes at the NMJ anticipate the retraction of
the motor axonB10 days later in the tONhFUSP525L mouse and
precede loss of MN somata. These data are consistent with a
model of axonal ‘die-back’ described in the SOD1 mutant by




















































































Figure 7 | Widespread postnatal deletion of FUS does not cause MN degeneration. (a) Experimental paradigm for early postnatal induction of CreERT2
activity. Mice were treated with tamoxifen at postnatal days 1–5 and were analysed at p240. (b) L5 spinal cords of p240 control (FUSFLOX/WT; UBC-
CreERT2þ / , left) and FUS-KOUBC (FUSFLOX/KO; UBC-CreERT2þ / , right) animals immunostained for FUS (red) and ChAT (white). Outlined areas of
top panels are reproduced at higher magnification in the bottom panels. Loss of FUS immunoreactivity was observed in 96.0±3.8% of NeuN-IR neurons
and 83.0±4.8% of NeuN-negative cells. N¼ 3. Scale bar, 200mm (top), 50mm (bottom). (c) The numbers of MNs in the L5 spinal cord normalized to
control (top) and the percentage of innervated NMJs in the tibialis anterior (TA) muscle (bottom) in p240 control (dark grey) and FUS-KOUBC (white)
animals. N¼ 3. (d) Representative images of L5 MNs in tONhFUSP525L/control (left) and tONhFUSP525L/FUS-KOUBC animals (right). (e) Percentage of
denervated NMJ’s in the TA muscle of tONhFUSP525L/control (red) and tONhFUSP525L/FUS-KOUBC (green) animals (N¼4 for all groups. For d and e, the
genotypes of the tONhFUSP525L/control and the tONhFUSP525L/FUS-KOUBC animals were tONhFUSP525L;FUSFLOX/WT;UBC-CreERT2þ / and
tONhFUSP525L;FUSFLOX/KO;UBC-CreERT2þ / , respectively.)
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neuronal loss in distinct subpopulations of MNs49. The
mechanism that underlies these early physiological and
morphological changes at the NMJ is not known, but
overexpression of mutant FUS has been reported to impair
axonal transport50–52. The reported roles of FUS in mRNA
transport and local translation17 are perturbed by ALS-associated
mutations53,54, suggesting that—as with mutant TDP-43
(ref. 20)—mutant FUS may impair the transport of mRNA to
the periphery and decrease axonal translation required for axonal
maintenance55.
The discovery of novel ALS genes leads first to the question of
whether causal mutations result in a loss of function of the
encoded protein or a gain of toxic properties, related or not to its
normal activity. Structural and functional similarities between
TDP-43, FUS and other ALS-associated RNA-binding proteins
encouraged the view that the role of these proteins in MN disease
relates to the normal RNA processing functions of these
regulatory factors. Physical interaction between FUS and
TDP-43 as well as evidence of their shared role in genetic
pathways required for survival and motor function56,57 further
implicated the normal activities of these proteins in MN survival
in ALS. These early observations led to the suggestion that
mutant FUS acts as a dominant negative to interfere with the
normal activity of the WT FUS protein to cause a partial or
complete loss of function, leading to MN degeneration in
ALS-FUS. Our data demonstrating that postnatal FUS
elimination has no effect on MN survival even in the most
vulnerable MN pools provide unequivocal evidence that
FUS loss-of-function alone does not underlie MN degeneration
in ALS.
In ALS patients, FUSP525L is associated with juvenile-onset and
rapidly progressive MN disease. In the tONhFUS mice, this allele
is also more pathogenic than hFUSR521C both in terms of onset
and progression of the MN degeneration. This provides further
evidence that the t-hFUS mice reliably model key aspects of
ALS-FUS. However, the basis of this enhanced toxicity is not
clear. In the t-hFUSP525L mice, mutant FUS is localized to the
cytoplasm to a much greater extent than hFUSR521C, and the
more pronounced MN phenotype is consistent with previous
studies that correlate toxicity with the degree of cytoplasmic
mislocalization of FUS58. However, although the accumulation of
cytoplasmic FUS correlates with the severity of the MN
phenotype in our model, we find no evidence that this is
associated with the formation of large cytoplasmic inclusions
characteristic of ALS-FUS.
Toxicity in the t-hFUS mice was also associated with an
increase in the steady-state level of mutant hFUS protein relative
to the hFUSWT control, which does not reflect a difference in the
levels of hFUS mRNA in the three tON-hFUS mice, but an
increase in the stability of hFUS conferred by ALS-causing
mutations—in agreement with a recent in vitro study59. However,
the selective toxicity of mutant hFUS does not appear to be a
quantitative/dose-dependent effect in this system as doubling of
hFUSWT levels in the homozygous tON mutant does not result in
MN degeneration, and twice the level of mutant hFUSP525L does
not exacerbate the MN phenotype. Rather, these data support a
mechanism by which ALS-related mutations confer qualitative
changes on hFUS that underlie the toxic gain of function.
Insight into the mechanism by which mutant FUS causes MN
degeneration in the tON mice comes from our finding that the
postnatal elimination of the endogenous FUS in our most severe
hFUSP525L mutant had no effect on the initiation and early
progression of MN loss. These data argue that mutant FUS
toxicity does not involve an excess of FUS activity, as suggested by
the finding that mutations in the 30UTR of FUS13 cause ALS by
perturbing the autoregulation of FUS expression60 and increasing
FUSWT levels13, and by previous studies showing that
overexpression of FUSWT is toxic to neurons. Our data also
demonstrate that the toxicity of mutant FUS does not depend on
a physical or functional interaction with the much more14,61
abundant endogenous FUS protein, arguing against the ‘seeding’
hypothesis of FUS toxicity by which mutant hFUS accelerates the
aggregation of mFUSWT, resulting in selective toxicity to MNs.
In light of our conclusion that the activity of FUS is not
required for the long-term survival of MNs, the question remains
then as to how the structural and functional similarities between
FUS-, TDP-43- and other ALS-associated hnRNP’s relate to their
role in the disease. One intriguing idea is that these ALS proteins
all contain low-complexity ‘prion-like’ sequences (and possibly
other domains62) that are not only a key determinant of their
normal function, but also of their role in the pathogenesis of ALS.
These domains appear to mediate the movement of these
regulatory proteins in and out of subcellular, RNA-containing
structures like stress granules43,44 and permit reversible and
regulated44,63,64 interactions with a large variety of partner
proteins. Under pathological conditions, these same regions may
mediate the irreversible formation of abnormal aggregates that
are selectively toxic to subpopulations of neurons. The natural
propensity of these proteins to anneal leads to a model of disease
in which the low probability of WT protein to form these toxic
aggregates is increased by disease-causing mutations, leading to
the onset of neurodegeneration7. Although our data does not
support the seeding of endogenous FUS by the mutant, aberrant
interactions of mutant hFUS with other factors could underlie
its toxicity, and the ALS-FUS models we present offer a
highly disease-relevant, in vivo system in which to explore these
interactions and to elucidate mutant FUS-dependent mechanisms
of disease.
Methods
Generation of mice and mouse genetics. All procedures were performed in
accordance with the National Institutes of Health Guidelines on the Care and Use
of Animals and approved by the Institutional Animal Care and Use Committee at
Columbia University.
The tOFFhFUS mouse lines were generated using a vector modified from that
designed to target the mouse MAPT (tau) genomic locus by homologous
recombination65. This targeting vector was modified to include a LoxP-flanked
transcriptional ‘stop’ sequence (poly-A3) followed by a myc-tagged human FUS
cDNA (hFUSWT, hFUSR521C or hFUSP525L generously provided by Brian McCabe).
The FUSFLOX mouse line in which FUS exons 4–6 are flanked by LoxP sites was
created from ES cells obtained from the International Knockout Mouse
Consortium Project: 84575.
Muscle innervation analysis. Cryosections of muscle (30 mm) were stained
with antibodies against VAChT to identify the pre-synaptic terminal, and
tetramethylrhodamine-conjugated a-BTX (Invitrogen) to detect post-synaptic
acetylcholine receptors. Images were acquired using Zeiss Pascal LSM 510 confocal
microscope using a  10 objective. Percentage (%)NMJ innervation was deter-
mined by dividing the total number of areas of overlap between VAChT and
a-BTX signals (total number innervated endplates) by the number of areas a-BTX
signal (total number of endplates).
MN counts. The lateral motor column of lumbar spinal segment L5 was imaged as
a z-series of confocal optical sections at a  20 magnification (z-step of 1.5 mm).
MNs labelled with an anti-ChAT antibody were counted by outlining the cell body
in the confocal plane of the nucleolus using ImageJ.
Electron microscopy. Animals were deeply anaesthetized using ketamine
(100mg kg 1) and xylazine (10mg kg 1) and transcardially perfused with 0.1M
PBS followed by 2.5% glutaraldehyde and 4% paraformaldehyde (EMS) in PBS. TA
muscles were post-fixed at 4 C overnight and sectioned using a vibrating blade
microtome (200 mm; Leica VT 1000S) and processed for reduced osmium
tetroxide-thiocarbohydrazide—osmium (ROTO) method66. After dehydration and
resin infiltration (EPON 812; EMS), samples were cured at 70 C for 3 days. Blocks
were sectioned in a UC7 Ultramicrotome (Leica) with a 35 Diamond knife
(Diatome). Ultra-thin serial sections (40 nm) were collected on Kapton66,
post-stained (1% uranyl acetate, 5min; 2% lead citrate, 1min), mounted in silicon
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wafers (Universal Wafers) and carbon coated (custom built coater). Backscattered
images were collected using ATLAS (FIBICS) at 3 nm pixel resolution (3ms dwell)
in a SIGMA FESEM electron microscope (Zeiss).
NMJ functional assays. Mice were terminally anaesthetized with isoflurane
followed by decapitation. The M-response in TA muscles was assessed in an
isolated sciatic nerve-hind-limb preparation in vitro. Muscles were perfused with
oxygenated (95%O2þ 5%CO2) artificial cerebrospinal fluid (CSF) (12.83mM NaCl,
0.4mM KCl, 0.05mM NaH2PO4, 2.1mM NaHCO3, 1.5mM CaCl2, 1mM MgSO4,
30mM glucose). A suction stimulating electrode was placed on the sciatic
nerve and EMG recordings were obtained using a concentric needle electrode
(P12CEA3, Microprobes) placed in the belly of the muscle. The maximum
M-response was obtained following stimulation of the sciatic nerve for 0.2ms at
supramaximal stimulus intensity. The signal was amplified ( 1,000; acquired
by MultiClamp 700B, Molecular Devices), filtered (0.1–3 kHz) and digitized for
offline analysis.
Spontaneous muscle activity was recorded for 60 s immediately after placement
of the EMG electrode. A two Standard Deviations (2s.d.) window discriminator of
the peak-to-peak baseline signal (calculated from 5 different and random time
points during EMG acquisition) was used to calculate spontaneous events above
the baseline recording.
Subsequently, a train of stimuli was delivered at 10, 50 and 100Hz to the sciatic
nerve for 1 s duration. The change of the M-response (measured peak-to-peak) at
different frequencies was calculated and expressed as a percentage change from the
first response for each frequency.
Statistical analysis. For all statistical tests, Graph Pad Prism 6 software was used.
Statistical analysis of mean differences between groups was performed using either
one- or two-way analysis of variance, followed by a Bonferroni post hoc analysis or
Fisher’s least significant difference (LSD) test depending on the number of variables
and time points in each experiment. The statistical tests, P values and n values are
indicated in figure legends.
See Supplementary Methods for details.
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